From surface to nuclear receptors: the endocannabinoid family extends its assets.
Peroxisome proliferator-activated receptors (PPARs) have long been known as mediators of several physiological functions, among which the best characterized are lipid metabolism, energy balance and anti-inflammation. Their rather large and promiscuous ligand binding site has been recently discovered to accommodate, among a plethora of lipid molecules and metabolic intermediates, endocannabinoids and their cognate compounds, specifically belonging to the Nacylethanolamine group. In fact, oleoylethanolamide, palmitoylethanolamide and probably anandamide bind with relatively high affinity to PPARs and have now been included among their endogenous ligands. Through activation of PPARs these molecules exert a variety of physiological processes. Particularly, both long-term effects via genomic mechanisms and rapid non-genomic actions have been described, which in several instances are opposite to those evoked by activation of "classical" surface cannabinoid receptors. In this review, we describe how these effects are relevant under diverse physiological and pathophysiological circumstances, such as lipid metabolism and feeding behaviour, neuroprotection and epilepsy, circadian rhythms, addiction and cognition. A picture is emerging where nuclear receptors are involved in anorexiant, anti-inflammatory, neuroprotective, anti-epileptic, wakefulness- and cognitive-enhancing, and anti-addicting properties of endocannabinoid-like molecules. Further studies are necessary to fully understand cellular mechanisms underlying the interactions between endocannabinoids and PPARs, but also between their surface and nuclear receptors, and to exploit their potential therapeutic applications.
Pistis
M
M
B.B. Brodie Department of Neuroscience and Center of Excellence for the Neurobiology of Addiction, University of Cagliari, Monserrato, Italy. mpistis@unica.it
Melis
M
M
D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology; D000927:Anticonvulsants / Q000737:chemistry / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000737:chemistry / Q000494:pharmacology; D001067:Appetite Depressants / Q000737:chemistry / Q000494:pharmacology; D063385:Cannabinoid Receptor Modulators / Q000737:chemistry* / Q000494:pharmacology; D063388:Endocannabinoids; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology; D047492:Peroxisome Proliferator-Activated Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*
D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D001067:Appetite Depressants; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D018696:Neuroprotective Agents; D047492:Peroxisome Proliferator-Activated Receptors